BACKGROUND. Few studies have considered etiological differences across molecular subtypes of prostate cancer, despite potential to improve opportunities for precision prevention of a disease for which modifiable risk factors have remained elusive. Factors that lead to DNA double-strand breaks, such as oxidative stress, may promote the formation of the TMPRSS2:ERG gene fusion in prostate cancer. We tested the hypothesis that increasing levels of pre-diagnostic circulating antioxidants, which may reduce oxidative stress, are associated with lower risk of developing TMPRSS2:ERG positive prostate cancer. METHODS. We conducted a nested case-control study, including 370 cases and 2,470 controls, to evaluate associations between pre-diagnostic a-and b-carotene, a-and g-tocopherol, b-cryptoxanthin, lutein, lycopene, retinol, and selenium with the risk of prostate cancer by ERG protein expression status (a marker of TMPRSS2:ERG). Multivariable unconditional polytomous logistic regression was used to calculate odds ratios and 95% confidence intervals. RESULTS. We did not find any of the antioxidants to be significantly associated with the risk of prostate cancer according to ERG status. CONCLUSIONS. The results do not support the hypothesis that circulating pre-diagnostic antioxidant levels protect against developing TMPRSS2:ERG positive prostate cancer. Additional studies are needed to explore mechanisms for the development of TMPRSS2:ERG positive disease.
INTRODUCTION
Gene fusions involving members of the ETS family of transcription factors define the largest molecular subgroup of primary prostate cancer [1] . TMPRSS2: ERG is the most common such gene fusion, occurring in 40-50% of primary tumors [2] . It is thus imperative to identify risk factors that could improve opportunities for precision prevention of TMPRSS2:ERG defined disease. Experimental evidence suggests that androgen exposure together with factors that lead to DNA double-strand breaks, such as radiation, promotes the formation of TMPRSS2:ERG [3] [4] [5] . Oxidative stress can induce double-strand breaks, lending plausibility to the hypothesis that increasing levels of circulating antioxidants, which may reduce oxidative stress, could be associated with a lower risk of developing TMPRSS2:ERG positive prostate cancer. Were this hypothesis true, then it could explain some of the mixed evidence regarding associations between antioxidants and prostate cancer overall [6] . I.e., if studies of antioxidants and prostate cancer have been conducted in populations with different prevalences of molecular subtypes, then one would expect to have found varying strengths of association. To evaluate the hypothesis, we conducted a nested case-control study of 370 prostate cancer cases and 2,470 controls assessing the associations between pre-diagnostic circulating levels of a-and b-carotene, a-and gtocopherol, b-cryptoxanthin, lutein, lycopene, and retinol and risk of prostate cancer by ERG protein expression status (a marker of TMPRSS2:ERG fusion status).
MATERIALS AND METHODS

Study Population
This study included prostate cancer cases with known ERG protein expression status and controls from several previous studies of pre-diagnostic circulating antioxidant levels nested within the Physicians' Health Study (PHS) and Health Professionals Followup Study (HPFS) cohorts [7] [8] [9] [10] [11] . The PHS was a randomized, double-blind, placebo-controlled trial of aspirin and b-carotene supplementation initiated in 1982 among 22,071 male physicians ages 40-84 [12] . The HPFS is an ongoing prospective cohort study of 51,529 male health professionals ages 40-75 at enrollment in 1986. Additional details of the cohorts can be found in the previously conducted studies [7] [8] [9] [10] [11] .
In the PHS, blood was collected from 68% of participants (n ¼ 14,916) prior to randomization, as previously described [13] . From among those who provided blood, incident prostate cancer cases (diagnosed through 2005) and controls were selected via risk-set sampling and additionally matched on age at baseline and smoking status (never, former, current). In the HPFS, blood was collected from 18,159 participants (35% of the cohort) free from prostate cancer between 1993 and 1995, as previously described [11] . From among those who provided blood, incident prostate cancer cases and controls who had had a prostate-specific antigen (PSA) test after blood draw were selected using risk-set sampling at three time points (1996, 1998, and 2000) . Cases and controls were additionally matched on year of birth, PSA test before blood draw (yes, no), timing of blood draw (midnightbefore 9 am, 9 am-before noon, noon-4 pm, and after 4 pm-before midnight), season of draw (winter, spring, summer, fall), and year of draw (exact).
In total, antioxidant data for at least one biomarker of interest were available for 1,749 cases and 2,511 controls. Of the cases, ERG tumor status was available for 375 (PHS: 209/HPFS: 166). After excluding 3 cases with T1a tumors, 2 cases and 22 controls who had a diagnosis of cancer other than non-melanoma skin cancer before the date of blood draw, 5 controls with missing index dates for matching, and 14 controls with a blood draw date after the date of their matched case's diagnosis, 370 unique cases and 2,470 unique controls remained for analyses. Among them, 11 individuals served both as a control prior to prostate cancer diagnosis and as a case.
This study was approved by the Human Subjects Committee at the Harvard T.H. Chan School of Public Health and by Partners Health Care. Written informed consent was obtained from each subject.
Measurement of Antioxidant Levels
The measurement of circulating antioxidants levels has been previously described in detail [7] [8] [9] [10] [11] . In brief, in the PHS, plasma was assayed for a-carotene, a-and g-tocopherol, b-cryptoxanthin, lutein, lycopene, and retinol in three batches [7, 8] . b-Carotene and selenium were assayed in two batches [9] . In the HPFS, a-and b-carotene, a-and g-tocopherol, bcryptoxanthin, lutein, and lycopene were assayed in three batches [10, 11] , and retinol and selenium were not measured. For samples from both the PHS and the HPFS, cases and their matched controls were analyzed together and laboratory personnel were unable to distinguish case, control, and quality control samples.
Tumor Tissue Collection and Assessment of TMPRSS2:ERG Status
In both the PHS and HPFS, prostate tumor tissue has been collected from participants having undergone radical prostatectomy or transurethral resection of the prostate (TURP). Tissue microarrays have been constructed by taking three or more 0.6-mm cores of tissue from the primary tumor nodule or nodule with the highest Gleason grade.
We characterized the presence or absence of TMPRSS2:ERG by immunohistochemical assessment of ERG protein expression as previously described [14] . Several studies have shown ERG protein expression to be strongly correlated with TMPRSS2: ERG fusion status as assessed by other methods [15] [16] [17] .
Statistical Analysis
We calculated batch-specific quartiles of antioxidants levels according to the distribution in the controls. We then used unconditional binary logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) for associations between plasma antioxidants and risk of prostate cancer overall, and unconditional polytomous logistic regression to study associations with three outcomes: ERG-positive prostate cancer, ERG-negative prostate cancer, and controls. To maximize power, we combined the two cohorts and adjusted for all matching factors used in either cohort. We also ran models additionally adjusted for body mass index (BMI) at blood draw and cohort. Missing data for covariates (<10% for all covariates) were assigned to the mode value for categorical variables and the median value for continuous variables. We conducted tests for linear trend by modeling quartile scores as continuous terms (0, 1, 2, or 3) and calculating the Wald statistic. To test for heterogeneity by ERG status, we evaluated the Wald statistic from comparing the trend parameters for ERG-positive disease versus control and for ERGnegative disease versus control. We ran sensitivity analyses restricted to Caucasian men, excluding 29 cases with ERG assayed in TURP specimens or tissue from an unknown source, excluding cases diagnosed within 1 year of blood draw, by cohort separately, and using conditional logistic regression of matched sets. Analyses were conducted using SAS version 9.2 (SAS Institute, Inc., Cary, NC). All tests were two-sided and P-values below 0.05 were considered statistically significant.
RESULTS
Characteristics of the 2,470 controls, 191 ERGnegative cases and 179 ERG-positive cases are presented in Table I . The mean time between blood draw and diagnosis for all cases was 7.6 years. Cases were more likely than controls to have ever had a PSA test prior to blood draw, and to have had their blood drawn in winter or summer; controls were more likely to have had their blood drawn in fall. Among cases only, as previously reported [14] , those who were ERG-positive were younger at diagnosis and had higher stage tumors relative to those who were ERGnegative. Batch-specific median antioxidant levels in both cases and controls are available in Supplementary Table SI. The cases excluded from our analyses because they lacked antioxidant and/or ERG expression data were more likely missing data regarding the clinical characteristics of their disease. In addition, their distribution of clinical stage was shifted slightly upwards, they were diagnosed in later years at an older age with higher PSA levels, and they were less likely to be treated with radical prostatectomy (data not shown). Polytomous models assessing the risk of ERGnegative and ERG-positive cancer separately did not suggest differential associations between any of the circulating antioxidants and risk of prostate cancer according to ERG status (Table II) . a-Tocopherol was non-significantly associated with a decreased risk of ERG-positive disease (OR Q4 vs. Q1 : 0.76; 95%CI: 0.48-1.20; P trend : 0.08), but not with the risk of ERGnegative disease (OR Q4 vs. Q1 : 1.03; 95%CI: 0.66-1.61; P trend : 0.82) (P diff : 0.13). All other P diff for differential associations according to ERG status were greater than 0.30. Results from all sensitivity analyses were materially unchanged.
DISCUSSION
In this first study to examine the relationship between circulating pre-diagnostic antioxidant levels and TMPRSS2:ERG defined prostate cancer, we did not find any significant associations. Our results do not support the hypothesis that higher circulating pre-diagnostic antioxidant levels protect against developing TMPRSS2:ERG positive prostate cancer specifically.
Our results are somewhat surprising in the context of two recent studies suggesting a relationship between exposures that reduce genotoxic stress and a lower risk of prostate cancer harboring TMPRSS2: ERG [18, 19] . In a study from our group, we found that the intake of tomato sauce, a substantial contributor to lycopene intake, is more strongly associated with ERG-positive than ERG-negative prostate cancer [18] . Similarly, Wright and colleagues determined that the use of aspirin, an anti-inflammatory medication [20] , is associated with a significantly reduced risk of TMPRSS2:ERG positive prostate cancer only [19] . It could be that tomato sauce and aspirin have properties other than antioxidants that contribute to a reduced risk of TMPRSS2:ERG positive disease. It is also possible that the specific circulating antioxidant exposures in the current study were not relevant to the risk of prostate cancer. In particular, antioxidant exposure at a different time point could be important in the development of TMPRSS2:ERG; antioxidants were measured an average of approximately 7-8 years before diagnosis in our study. Our results could also be explained by chance.
Although our results for pre-diagnostic circulating antioxidant levels were largely null, it remains [21] . It could be that the local increase in oxidative stress precipitated by increased androgen signaling outweighs any potentially beneficial effects of high circulating antioxidant levels for TMPRSS2:ERG positive disease. Moreover, the tissue microenvironment in which tumors develop is a critical factor in cancer initiation and progression [22] . Our lack of association in this study could be explained by our lack of data regarding the tumor microenvironment.
An additional possibility is that the TMPRSS2:ERG gene fusion may not directly result from oxidative stress. Androgen signaling has previously been associated with co-recruitment of androgen receptor and topoisomerase II beta (TOP2B) and with TOP2B-mediated DNA double-strand breaks at sites of the fusion [23] . It could be that these strand breaks lead to the formation of TMPRSS2:ERG in a manner independent of strand breaks induced by oxidative stress. It also possible, however, that TOP2B is recruited to the site of TMPRSS2:ERG fusions in response to strand breaks resulting from genotoxic insults.
We did observe some indication that increasing a-tocopherol levels could be exclusively associated with ERG-positive prostate cancer. Again, the suggestive results could be due to chance alone. A priori, we did not anticipate that a-tocopherol would stand out from the other antioxidants evaluated in this study. However, a recent pooled analysis of circulating carotenoids, retinol, and tocopherols found only a-tocopherol to be associated with a significantly reduced risk of prostate cancer [24] . It could be that the foods that contribute to circulating a-tocopherol levels have other components that affect prostate cancer risk, and specifically the risk of TMPRSS2:ERG positive prostate cancer.
This study was limited by the relatively small number of cases assayed for ERG status. We also measured ERG protein expression rather than the TMPRSS2:ERG fusion itself, but the former has been shown to have high concordance with the latter as assessed by alternative methods [15] [16] [17] . It is also important to note that cases assayed for ERG status are largely those treated with radical prostatectomy. As a result, they may not be representative of all men diagnosed with prostate cancer. Still, our study was borne from a well-annotated prospective cohort with tumor tissue, plasma, and clinical data. We were able to measure circulating antioxidant levels prior to diagnosis, thereby sidestepping any issues of reverse causation, and we adjusted for potentially important confounding variables.
CONCLUSIONS
In summary, we did not find credible evidence that pre-diagnostic circulating antioxidant levels are associated with the risk of TMPRSS2:ERG defined prostate cancer. Additional studies are needed to explore mechanisms for the development of disease positive for the fusion.
